CTOs on the Move

Alliance Boots

www.allianceboots.com

 
Alliance Boots is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Velocity Clinical Research

Velocity Clinical Research, headquartered in Durham, NC, is a leading integrated site organization for clinical trials, offering dedicated site capabilities to help biopharmaceutical and contract research organization customers find the right patients for their studies. The company has 18 sites across 12 US States. We place the care of the patient at the heart of everything we do. With over 35 years of experience running sites and more than 5500 studies completed, Velocity has refined its patient recruitment strategies while maintaining a focus on delivering timely and reliable data quality.

Precision BioLogic

Precision BioLogic is a Dartmouth, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DestinationRX

DestinationRX is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Virtus Pharmaceuticals

Virtus Pharmaceuticals’ mission is to be the leading specialty niche pharmaceutical company providing the highest quality products through experienced leadership, innovative approaches and outstanding customer service.

Dicerna

Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, GalXC™, is a platform that uses the body`s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. We have qualified dozens of disease-associated genes in clinical indications where we believe an RNAi-based inhibitor may provide substantial benefit to patients, providing expansive therapeutic opportunities. Dicerna is advancing a growing pipeline of product candidates based on our GalXC platform to deliver transformative therapies to patients. Dicerna brings together talented experts in biology, chemistry, clinical science and medicine. With decades of scientific and technical experience focused on RNAi technology, our team has the knowledge and experience needed to discover, develop and commercialize safe and effective therapies for patients with serious unmet medical needs. Our purpose is clear: delivering life-changing therapies as efficiently as possible to meet the urgent needs of people living with debilitating genetic diseases.